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ABSTRACT 
 
Background/Aim: Migraine is a risk factor for the formation of silent brain white matter 
lesions (WMLs) that are possibly ischemic in nature. Although dysfunction of the L-
arginine/nitric oxide (NO) pathway has been associated with oxidative stress and endothelial 
dysfunction in migraine, its role in WML development was not specifically investigated. 
Thus, this prospective study aimed to measure the serum concentrations of the NO substrate 
L-arginine, the NO synthase inhibitor asymmetric dimethylarginine (ADMA), and the L-
arginine transport regulator symmetric dimethylarginine (SDMA) in migraine patients in a 
headache-free period.  
Methods: All subjects underwent MR imaging to assess for the presence of WMLs on fluid-
attenuated inversion recovery imaging. Altogether 109 migraine patients (43 with lesions, 66 
without lesions) and 46 control subjects were studied. High-performance liquid 
chromatography was utilized to quantify L-arginine, ADMA and SDMA serum 
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concentrations. Migraine characteristics were investigated, and participants were screened for 
risk factors that can lead to elevated serum ADMA levels independent of migraine. 
Results: Migraine patients and controls did not differ in regard to vascular risk factors. 
Migraineurs with WMLs had a longer disease duration (P < .001) and a higher number of 
lifetime headache attacks (P = .005) than lesion-free patients. Higher L-arginine serum levels 
were found in both migraine subgroups compared to controls (P < .001). Migraine patients 
with WMLs showed higher ADMA concentrations than lesion-free patients and controls (P < 
.001, for both). In migraineurs, the presence of WML, aura and increasing age proved to be 
significant predictors of increased ADMA levels (P = .008, .047 and .012, respectively). 
SDMA serum levels of lesional migraineurs were higher than in nonlesional patients (P < 
.001). The presence of lesion and increasing age indicated an increased SDMA level (P = .017 
and .001, respectively. Binary logistic regression analysis showed that ADMA level (P = 
.006), increasing age (P = .017), and the total number of lifetime migraine attacks (P = .026) 
were associated with an increased likelihood of exhibiting WML. There was no significant 
effect of age on ADMA and SDMA concentrations in controls. 
Conclusions: Elevated ADMA levels may impact the pathogenesis of migraine-related 
WMLs by influencing cerebrovascular autoregulation and vasomotor reactivity. Higher 
SDMA concentrations may indirectly influence NO synthesis by reducing substrate 
availability. Elevated L-arginine serum levels might reflect an increased demand for NO 
synthesis.  
Keywords: migraine, white matter lesion, ADMA, SDMA, L-arginine, oxidative stress, 
vascular endothelial dysfunction 
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INTRODUCTION 
Migraine is a primary headache disorder with recurrent headache attacks (1). Migraine is an 
independent risk factor for the development of silent brain white matter lesions (WMLs) and 
infarcts (2-8). As such, WMLs are more prevalent in migraine patients than in the general 
population (2,3), and they can develop at any age during the active migraine years (3,9). 
Migraine, especially with aura, carries an increased risk for cerebro- and cardiovascular 
diseases that cannot be explained by traditional vascular risk factors (10-12). Although 
histopathological data are lacking in migraine, the microvascular ischemic injury theory 
(5,13) was supported by our previous quantitative magnetic resonance imaging (MRI) data 
demonstrating intralesional tissue damage (14) consistent with previous studies of WMLs of 
ischemic origin (15,16). In addition, longitudinal assessment of the same migraine patient 
group showed intralesional and intracerebral progression of WMLs over time (17). 
 A vascular etiology, such as impairment of the L-arginine/nitric oxide (NO) pathway 
with vascular endothelial dysfunction could explain the development and progression of 
WMLs, and could also provide a link between migraine and ischemic stroke or coronary heart 
disease. Endothelial NO-synthase (eNOS) utilizes L-arginine to generate the strong 
vasodilator, anti-atherogenic NO (18). Methylated analogs of L-arginine, symmetric and 
asymmetric dimethylarginine (SDMA and ADMA) are modulators of the L-arginine/NO 
pathway (19,20). Both ADMA and SDMA levels are associated with an increased 
cardiovascular risk and mortality (19,21). ADMA has also been found to be a marker of 
oxidative stress and endothelial dysfunction in migraine (21,22).  
 Despite the growing evidence of oxidative stress and vascular endothelial activation in 
migraine (23-27), the abovementioned biomarkers of endothelial dysfunction have not been 
comprehensively analyzed in relation to WMLs. Therefore, our objective in the present study 
was to quantify the L-arginine, ADMA and SDMA serum concentrations of migraine patients 
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with or without cerebral WMLs in a headache-free period, to detect group differences 
between lesional and non-lesional migraineurs, to investigate the effect of migraine 
characteristics, and to determine the differences between migraine patients and controls.  
PATIENTS AND METHODS 
Subjects 
Between 2010 and 2013, a total of 177 patients fulfilling the International Headache Society 
(IHS) classification criteria for migraine with or without aura (1) were screened from the 
Outpatient Headache Clinic of the Department of Neurology, University of Pécs. A total of 
109 migraineurs (93 females, mean age 36.7 ± 10.8 years, age range 19-65 years; Table 1), 82 
without and 27 with aura subtype remained and were prospectively enrolled in the study after 
exclusion of those with: (i) concurrent non-migraine headache types, (ii) focal neurological 
signs, (iii) abnormal screening blood test findings (e.g., abnormal lipid profile, etc.), (iv) 
suffering from any chronic disease other than medically treated hyperlipidemia or 
hyperuricemia, (v) active smoking habit. Patient selection was not restricted by age, since 
WMLs can be formed at any age during the active migraine headache years (9,10). Since the 
migraineurs were either newly-diagnosed, or established patients with low headache 
frequency (≤ 2/month) maintaining adequate control on acute migraine regimens, none of 
them were on chronic prophylactic therapy during the study period. For acute migraine 
treatment, eletriptan, sumatriptan, ibuprofen, diclofenac and acetaminophen were utilized. As 
controls, 56 subjects were screened, and 46 age-matched healthy subjects (33 females, mean 
age 37.5 ± 10.5 years, age range 20-65 years) were enrolled. These subjects were previously 
recruited via bulletin board advertisements throughout the University of Pécs accessible to 
students and staff. They had no history of any type of headache and passed the above-
mentioned exclusion criteria. All participants underwent detailed clinical investigations to 
uncover vascular risk factors, which themselves may cause elevation of serum 
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dimethylarginine levels and WMLs. All subjects with previously diagnosed 
hypercholesterolemia were treated with statins, and those with elevated uric acid levels were 
on allopurinol at the time of blood sampling. The clinical data of patients and controls are 
presented in Table 1, while migraine characteristics are seen in Table 2.  
All included participants underwent brain MRI in a headache free period utilizing the 
same scanner and acquisition protocol to evaluate the presence of white matter 
hyperintensities. Given the previous findings of focal tissue damage (14,17), we will refer to 
these as WMLs later in the text. WMLs were detected in 43 migraineurs, whereas no WMLs 
or other structural abnormalities were found in the rest of the studied population including 
controls.  
Migraine patients were divided into two subgroups based on presence of WMLs (L+) or 
absence of those (L-). Presence of aura, disease duration in years and monthly attack 
frequency were investigated, followed by the estimation of lifetime migraine attack number 
(average monthly attack number x 12 x number of migraine disease years to date) in all 
migraineurs. 
Serum levels of L-arginine, ADMA and SDMA were quantified from fasting blood 
samples taken between 8 and 9 a.m. by venipuncture from the antecubital vein in all enrolled 
participants. Patients were headache free for at least 3 days before blood sampling. The MR 
scanning and the taking of blood samples were performed on the same week.  
MR scanning protocol and identification of white matter lesions 
A 3.0-Tesla clinical MRI scanner (Magnetom TIM Trio, Siemens Medical Solutions, 
Erlangen, Germany) with a 12-channel phased-array head coil was used for MR image 
acquisitions. Routine T1-, T2-weighted and fluid-attenuated inversion recovery (FLAIR) 
imaging were performed. For standard and accurate axial slice positioning the anterior and 
posterior commissural line (AC-PC line) was used as a reference for T2-weighted and FLAIR 
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images. Sagittal T1-weighted images were obtained using a fast low angle shot (FLASH) 2-
dimensional (2D) sequence: TR/TE = 300/2.46 ms; flip angle = 88°; 27 slices; slice thickness 
= 4 mm; distance factor = 30%; Field of View (FOV) = 220x220 mm2; matrix size = 
256x320; receiver bandwidth = 330 Hz/pixel. For T2-weighted images a turbo spin echo 
sequence was used: TR/TE = 6000/93 ms, 30 slices, slice thickness = 4 mm, distance factor = 
20%, FOV = 193x220 mm2, matrix size = 280×320, bandwidth = 220 Hz/pixel, number of 
echo trains = 18. A turbo spin echo sequence was also used for the FLAIR images: TR/TI/TE 
= 15710/2750/105 ms, 100 slices, slice thickness = 1.5 mm, distance factor = 0% (no gap), 
interleaved slice readout with two concatenation, FOV = 220x220 mm2, matrix size = 
192×192, bandwidth = 400 Hz/pixel, number of echo trains = 14.  
 Two qualified neuroradiologists who were blinded to migraine diagnosis and clinical 
data rated the white matter lesions. WMLs were considered if visible as hyperintense areas on 
T2-weighted and FLAIR images without hypointensity on T1-weighted scans and larger than 
3 mm appearing in at least two consecutive slices (2) (Figure 1).  
Measuring serum concentrations of dimethylarginines and L-arginine 
The amino acids were extracted from the blood serum via solid phase extraction (SPE) 
according to the method of Nonaka et al. (28): a mixture of 250 µL serum sample and 700 µL 
borate buffer (pH = 9.00) was mixed with the internal standard that was L-homoarginine 
hydrochloride (Aldrich, Germany) and 50 µL of 1000 µmol/L solution was applied. Then the 
mixture with the internal standard was passed through SPE cartridges (OASIS® MCX 3cc 
SPE) at 750 mbar in a 12-column manifold (J. T. Baker). The elution was performed by 
concentrated aqueous ammonia (Reanal, Hungary), water and methanol with a volume ratio 
of 10/40/50. The solvent was evaporated beginning under a nitrogen atmosphere and finished 
in a vacuum at 60 °C. The dry residue was dissolved in 200 µL deionized water (Millipore, 
Milli-Q) and derivatized according to Molnar-Perl et al. (29); at room temperature the 
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reaction time was 10 minutes. The high-performance liquid chromatography (HPLC) analysis 
was performed with a Waters 2695 Separations Module equipped with a thermostable 
autosampler (5 °C) and column module (35 °C). Separation was achieved with a Waters 
Symmetry SB C18 (4.6 x 150 mm, 3.5 µm) column and detected by a Waters 2475 
fluorescence detector (Waters Milford, MA, USA) (30). For the measurements, 10 µL was 
injected from the samples and the gradient elution was applied during the analysis with two 
mobile phases: A (20 mM (NH4)2CO3 in water, pH = 7.50 ± 0.05) and B (acetonitrile). The 
gradient program was as follows: 0-16 min: 91% A and 9% B, 16-17 min: linear change to 70 
% A and 30 % B and hold this for 5 minutes, 22-23 min: linear change to 91 % A, 9% B and 
hold this for 12 minutes. The flow rate was constant (1 mL/min). Arginine and homoarginine 
were detected at λex = 337 nm, λem = 520 nm, but λem = 454 nm was used for ADMA and 
SDMA. 
Statistical analysis 
Statistical analyses were performed utilizing the IBM SPSS Software (version 21, SPSS Inc, 
Chicago, IL). First, the distribution of each studied variable was assessed using the 
Kolmogorov-Smirnov and Shapiro-Wilk tests. Differences in age between the whole migraine 
group and healthy controls were assessed by the Mann-Whitney U-test.  
Univariate analyses. Differences of continuous variables (e.g., age, BMI, disease 
duration, migraine attack frequency, total number of migraine attacks, L-
arginine/ADMA/SDMA levels) among groups (L+, L-, control) were compared using the 
Kruskal-Wallis test followed by the Mann-Whitney U test. Differences in binary population 
characteristics (e.g., gender, smoking, hypercholesterolemia, hyperuricemia, elevated CRP 
level) among the same groups were assessed utilizing Pearson’s chi-square test.  
Multivariate analyses. First, we tested predictors of L-arginine/ADMA/SDMA levels 
using stepwise multiple linear regression analyses. Age, gender, disease duration, migraine 
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attack frequency, total number of migraine attacks and presence of aura were included as 
independent variables along with the grouping variable (L+ vs. L-), and L-
arginine/ADMA/SDMA level as the dependent variable. Similar analyses were performed to 
assess the L-arginine/ADMA/SDMA level differences between patient and control groups 
(L+ vs. control and L- vs. control), excluding migraine characteristics (not present in the 
control group) from the list of independent variables. In the control group, multiple linear 
regression analyses were performed to assess the potential effects of age and gender on L-
arginine, ADMA, and SDMA concentrations. Serum concentrations served as dependent, 
while age and gender as independent variables. The assumptions of multiple linear regression 
were satisfied, as judged by testing for linearity, and normality. In addition, in the patient 
group, binary logistic regression was performed including the covariates of age, gender, L-
arginine/ADMA/SDMA levels, disease duration, frequency of migraine attacks, total number 
of migraine attacks and presence of aura to assess the likelihood of WML presence. The final 
covariates were selected using a stepwise method (forward conditional).  
Finally, Spearman’s correlations were performed to assess the internal dependencies 
between the three reported lab-variables (L-arginine, ADMA, SDMA) in all subjects, and to 
investigate the correlation between age and disease duration in the migraine group. The level 
of statistical significance was set as < .05. 
RESULTS 
Age 
Since the age of controls was matched to the whole migraine group, there was no significant 
difference in age between them. The Kruskal-Wallis test revealed significant age differences 
among migraine subgroups and controls (P < .001) (Table 1). Post-hoc testing indicated 
significant differences between all possible pairs of the three groups (P < .05).  
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Control group 
Since the study subgroups were not age-, and gender-matched, the healthy control group was 
investigated next by multiple linear regression. There were no significant effects of either age 
or gender on L-arginine, ADMA, or SDMA concentrations; there were no interactions 
between age and gender (i.e. age*gender). 
Categorical data 
Regarding the gender of the subjects, and the presence of vascular risk factors, no significant 
differences were found among the groups (Table 1). 
Migraine characteristics 
Compared to lesion-free migraineurs, patients with WMLs had a longer disease duration (P < 
.001; Table 2), and a higher number of lifetime headache attacks (P = .005; Table 2). The 
attack frequency did not show a significant difference between the L+ and L-groups (Table 
2).  
L-arginine levels 
Markedly higher blood serum concentrations were measured in the migraine groups (L+ 
173.6 ± 55.6, L– 164.8 ± 53.4) than in the control group (107.7 ± 22.53) (P < .001, in all 
comparisons; Table 2, Figure 2). Statistically significant differences were not found between 
the migraine groups (Table 2, Figure 2). Since the multiple linear regression analyses revealed 
no additional significant predictors (e.g., age, gender), the pattern of significance remained 
unchanged. 
ADMA levels 
L+ migraine patients (0.781 ± 0.155) showed higher serum concentrations than L- patients 
(0.650 ± 0.159) and controls (0.663 ± 0.077) (P < .001, in both comparisons) (Table 2, Figure 
2). Controlling for the relevant covariates using multiple linear regression analyses, there was 
no change in the pattern of significance. When comparing the L+ group to the control group 
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no additional significant predictors (e.g., age, gender) were found. In the comparison of the 
L+ and L- groups, aura and age proved to be additional significant predictors; the presence of 
WML, aura and increasing age indicated an increased ADMA level (P = .008, .047 and .012 
respectively). There were no interactions between the independent variables.  
SDMA levels 
SDMA levels of L+ migraineurs (0.559 ± 0.094) were higher than L- patients (0.488 ± 0.106) 
(P < .001) and controls (0.520 ± 0.047), but the latter comparison was not statistically 
significant (P = .07) (Table 2, Figure 2). SDMA levels of controls were higher than L- 
patients (P = .017).  When comparing L+ and L- groups using a multiple linear regression 
model, age proved to be an additional significant predictor; the presence of lesions and 
increasing age indicated an increased SDMA level (P = .017 and .001, respectively). 
Comparing the L- and control groups, age proved to be a significant predictor (increasing age 
associated with increased SDMA level, P = .011), but the group difference (i.e., L- vs. 
control) was no longer significant (P = .145). A significant interaction was found between the 
grouping variable and age (P = .037). 
Binary logistic regression analysis 
The logistic regression model explained 37.4% (Nagelkerke R2) of the variance in WMLs and 
correctly classified 71.6% of WMLs. ADMA levels were the most significant independent 
predictors of WML presence, with more than an 85-fold higher likelihood of exhibiting 
WMLs in those with a 1 µmol/L elevation in ADMA (Exp(B) = 85.33, P = .006). Increasing 
age and total number of migraine attacks were also associated with an increased likelihood of 
exhibiting WML (Exp(B) = 1.06, P = .017 and Exp(B) = 1.001, P = .026, respectively). There 
were no interactions between the independent predictors. None of the other examined 
variables added significantly to the model. 
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Spearman’s correlations 
The ADMA level was positively correlated with both L-arginine and SDMA levels (ρ = .158, 
P < .05 and ρ = .403, P < .001, respectively). No significant correlation was found between 
the L-arginine and SDMA levels. A significant positive correlation was found between age 
and disease duration in the whole migraine group (ρ = .628, P < .001) and in both subgroups 
(L+, ρ = .703, P < .001; L-, ρ = .479, P < .001), as well.  
DISCUSSION 
The main finding of the present study is the elevated serum ADMA concentration in migraine 
patients with WMLs outside the attack period. ADMA levels were the best predictor of 
WMLs, independent of other significant factors such as age and estimated life-time headache 
attack number. Higher SDMA serum levels distinguished lesional migraine patients from 
lesion-free patients, while the elevated L-arginine concentrations differentiated migraineurs 
from controls.  
Age, vascular risk factors, migraine characteristics 
Increasing age was associated with an increased likelihood of exhibiting WMLs, and older 
age proved to be a predictor of higher ADMA and SDMA in migraineurs with lesions. Since 
positive correlation was found between age and disease duration, and there were no 
significant effects of age on ADMA and SDMA concentrations in controls, long duration of 
migraine, rather than older age, may explain the elevation of dimethylarginines.    
 Increased plasma ADMA concentrations have been associated with the presence of 
numerous vascular risk factors and chronic diseases such as obesity, hypertension, diabetes, 
dyslipidemia, hyperhomocysteinemia, ischemic heart disease, transient ischemic attack, silent 
brain infarcts, ischemic stroke, renal and liver failure, smoking and physical inactivity 
(19,31). Vascular risk factors were rare in both patients and controls in our study, and all of 
them were treated during the study period. It is known that lipid-lowering therapy and 
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smoking cessation reverse the endothelial dysfunction, if present (32). Therefore, a significant 
influence of vascular risk factors on the findings is unlikely.  
 In the present study, migraine patients with WMLs had a longer disease duration 
than nonlesional patients, and it was associated with a higher number of lifetime headache 
attacks. The number of lifetime headache attacks proved to be an independent predictor of 
WMLs, while the presence of aura indicated higher ADMA levels in migraineurs. Beyond the 
investigated migraine parameters, there are other factors such as attack intensity and duration, 
frequency and severity of the cortical spreading depression, which may have an influence on 
lesion formation. In concordance with previous studies (22,27), the interictal elevation of 
ADMA in lesional patients indicate that oxidative stress can be present in both the ictal and 
interictal phases in migraine.  
Effects of migraine on the biosynthesis and metabolism of dimethylarginines and L-
arginine 
NO is produced by vascular endothelial cells, and plays a crucial role in the regulation of 
blood pressure, cerebral blood flow and neuroprotection (18,33). The amino acid L-arginine is 
the main precursor of NO (Figure 3) (20,34). Posttranslational methylation of arginine 
residues on nuclear proteins leads to the generation of ADMA, SDMA and N-monomethyl-L-
arginine (L-NMMA) that are released into the cytosol upon proteolysis, then migrate into the 
extracellular space and thence into the blood plasma (35). Both ADMA and the less potent L-
NMMA are competitive inhibitors of all three isoforms of NOS, thus lowering the NO levels 
(35). The concentration of ADMA and L-NMMA is regulated mainly by degradation in the 
endothelial cells by the dimethylarginine dimethylaminohydrolase-2 isoform (DDAH-2), and 
in a smaller degree by urinary excretion (35,36). SDMA is the structural counterpart of 
ADMA, and like ADMA, blocks cellular L-arginine uptake competitively, thus indirectly 
influencing NO bioavailability by reducing substrate availability (37-39).  
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Since DDAH-2 is sensitive to oxidative stress triggered by the excessive generation of 
NO, under pathophysiological conditions, e.g., cardiovascular diseases and migraine, reactive 
O2 species (ROS) inhibit DDAH-2 activity with corresponding accumulation of ADMA (35). 
It is conceivable that the NO-caused vasodilatation is overbalanced by the increased amount 
of ADMA during migraine headache which may lead to a reduced bioavailability of NO, 
vasoconstriction with cerebral hypoperfusion and endothelial dysfunction (22). Since 
elevation of NO and ADMA concentrations are not restricted to the ictal state (22), inhibition 
of eNOS can also be present in a headache-free period. Chronic endothelial dysfunction has a 
role in mediating impaired cerebral autoregulation, and in the small perforating cerebral blood 
vessels it could result in poor white matter blood supply and the accumulation of white matter 
injury (40,41).  
 It is probable that migraine is a systemic factor of vascular endothelial injury and WML 
development during the active headache years. Our findings support the importance of 
migraine headache management to avoid vascular complications of migraine. This includes 
not only acute and prophylactic headache treatments, but also the pharmacotherapy of 
comorbid cerebro- and cardiovascular diseases, as well as lifestyle changes.  
Comparability of serum and plasma L-arginine and dimethylarginine measurements 
The samples were measured with the internal standard method using L-homoarginine as the 
internal standard in the present study. L-homoarginine with its similar structure and chemical 
properties to ADMA, SDMA and L-arginine provides a chance to eliminate the matrix effects 
and the loss of the components during the sample preparation. Furthermore, the calibrants 
were prepared the same way as the samples. Thus, it can be assumed that there is no 
significant influence on the comparability of the results because the matrix effect can be 
eliminated. 
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Study limitations 
The lack of age- and sex-matched study subgroups may limit the comparability of groups. 
Although hyperhomocysteinemia is a cardiovascular risk factor, blood homocysteine levels 
were not measured in the present study.  
Conclusion  
The elevated ADMA levels in lesional migraineurs may indicate a role of migraine-related 
vascular endothelial dysfunction in the development of WMLs, supporting the ischemic injury 
theory of WML formation. These findings indicate that elevated ADMA concentrations may 
be a risk factor for clinically silent brain WMLs and point out the necessity of therapeutic 
interventions. SDMA may also have a role in lesion formation by indirect inhibition of NO 
bioavailability. The higher L-arginine serum concentrations might reflect an increased 
demand for NO synthesis in migraine.  
Clinical implications  
 
• Elevated ADMA concentrations may be a risk factor for clinically silent brain WMLs.  
• Detection of ADMA levels in the clinic may help to estimate the risk of vascular 
endothelium impairment in migraineurs.  
• The elevation of ADMA in migraine patients with lesions point to the importance of 
the clinical management of migraine headache and the pharmacotherapy of comorbid 
cerebral and cardiovascular diseases. 
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Table 1. Clinical data of migraine patients and healthy controls and differences among groups 
 
 
Investigated            Migraine patients      Migraine patients          Controls         Differences 
parameters               with lesions           without lesions                            (P - value) 
                          (n = 43)              (n = 66)              (n = 46)        
 
Age (years)               41.7 (21 - 65)           32.7 (19 - 54)          37.5 (20 - 65)        < .001' 
 
Female/male                 38/5                 55/11                 33/13              .107" 
 
Hypertension                 0/43                 0/66                   0/46              N/A               
 
Diabetes                     0/43                 0/66                   0/46              N/A 
 
Kidney disease               0/43                 0/66                   0/46              N/A 
 
Hepatopathy                 0/43                 0/66                  0/46              N/A 
 
High LDL cholesterol*         5/43                 6/66                     2/46                .886" 
 
Hyperuricemia**             1/43                 2/66                   3/46                 .660" 
 
Elevated CRP level***        2/43                 5/66                   2/46                .228" 
 
Thyroid disorder              0/43                 0/66                   0/46              N/A 
 
Systemic autoimmune         0/43                 0/66                  0/46              N/A 
disease 
 
Smoking****                6/43                 8/66                  5/46                .445" 
 
Cardiac source                0/43                 0/66                  0/46              N/A 
of embolism 
 
BMI (kg/m2)             23.69 ± 2.21          23.29 ± 2.46            23.65 ± 2.12           .267' 
  
LDL: low-density lipoprotein;  CRP: C-reactive protein; BMI: body mass index; N/A: Not Applicable; Participants were treated with  
statins* (LDL < 3.4 mmol/l) and allopurinol** (uric acid < 350 mmol/l) at the time of blood sample taking; ***CRP was between  
5.0 and 7.0 mg/l in elevated cases; ****History of smoking, no active smoking ; 'Kruskal-Wallis test; "Pearson’s chi-square test  
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Table 2. Results of measured variables and statistical differences between migraine subgroups and controls 
 
White matter lesions Statistics 
Lesion+ (n = 43)* Lesion- (n = 66)** Control (n = 46) Mann-Whitney test 
Kruskal-Wallis test 
Mean SD Mean SD Mean SD L+ vs. L- L+ vs. C L- vs. C 
Disease duration 
(years) 
20.12 11.84 11.98 7.45 - - < .001 - - < .001 
Migraine attack 
frequency/month 
3.88 3.24 3.43 3.04 - - .45 - - .45 
Total number of 
migraine attacks 
900.3 913.4 428.4 398.5 - - .005 - - .005 
L-arginine 173.6 55.6 164.8 53.4 107.7 22.53 .55 < .001 < .001 < .001 
ADMA 0.781 0.155 0.650 0.159 0.663 0.077 < .001 < .001 0.48 < .001 
SDMA 0.559 0.094 0.488 0.106 0.520 0.047 < .001 0.07 0.017 < .001 
ADMA = asymmetric dimethylarginine; SDMA = symmetric dimethylarginine; *13 migraine patients with aura; **14 migraine patients with aura 
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Figure 1. Axial fluid-attenuated inversion recovery brain MRI images of a migraine patient with aura. The 
figure shows bifrontal white matter hyperintensities in two different slices (A and B).  
93x58mm (300 x 300 DPI)  
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Figure 2. L-arginine, asymmetric and symmetric dimethylarginine (ADMA and SDMA) serum concentrations 
in migraineurs and controls. The figure demonstrates the differences between the lesion+, and the lesion- 
migraine groups and the control group. Whiskers are set at minimum and maximum, the horizontal line 
marks the median, whereas the box indicates the interquartile range (25–75%). The statistically significant 
differences between the groups are indicated by * on the figures (*P < .05, ***P < .001).  
78x22mm (300 x 300 DPI)  
 
 
Page 24 of 28
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 3. Effects of migraine headache on the biosynthesis and metabolism of dimethylarginines and L-
arginine. SAM = S-adenosyl-methionine, SAH = S-adenosyl-homocysteine, PRMTs = protein arginine 
methyltransferases, ADMA = asymmetric dimethylarginine, L-NMMA = N-monomethyl-L-arginine, SDMA = 
symmetric dimethylarginine, NO = nitric oxide, DDAH-2 = dimethylarginine dimethylaminohydrolase-2, 
eNOS = endothelial nitric oxide synthase.  
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No. Recommendation 
Page  
No. 
Relevant text from 
manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1 prospective 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found 
1-2  
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 3  
Objectives 3 State specific objectives, including any prespecified hypotheses 3-4  
Methods  
Study design 4 Present key elements of study design early in the paper 4-5  
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, 
follow-up, and data collection 
4-8  
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of 
participants 
 
 
4-5 
 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per 
case 
 
 
4-5 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. 
Give diagnostic criteria, if applicable 
4-7  
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group 
4-7  
Bias 9 Describe any efforts to address potential sources of bias 4-8  
Study size 10 Explain how the study size was arrived at 4-5  
Continued on next page   
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11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why 
4-7  
Statistical 
methods 
12 (a) Describe all statistical methods, including those used to control for confounding 7-8  
(b) Describe any methods used to examine subgroups and interactions 7-8  
(c) Explain how missing data were addressed No missing 
data 
 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy 
 
4-5, 7-8 
 
(e) Describe any sensitivity analyses NA  
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
4-5, 8-9  
(b) Give reasons for non-participation at each stage NA  
(c) Consider use of a flow diagram NA  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders 
4-5, 8-11  
(b) Indicate number of participants with missing data for each variable of interest NA  
(c) Cohort study—Summarise follow-up time (eg, average and total amount) NA  
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time NA  
Case-control study—Report numbers in each exposure category, or summary measures of exposure 8-11  
Cross-sectional study—Report numbers of outcome events or summary measures NA  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision 
(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were 
included 
8-11  
(b) Report category boundaries when continuous variables were categorized NA  
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
NA  
Continued on next page   
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For Peer Review
 3 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 8-11  
Discussion 
Key results 18 Summarise key results with reference to study objectives 11-14  
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
13-14  
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
14  
Generalisability 21 Discuss the generalisability (external validity) of the study results 14  
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based 
14  
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
Page 28 of 28
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
